This is an antibacterial drug-mechanism module, not a specific disease. Disorder entries reference individual nodes via conforms_to (e.g., "bacterial_protein_synthesis_inhibition#Bacterial mRNA Translation by the Ribosome"), and their ribosome-targeting treatments point at the inhibited node via target_mechanisms. Two key conformance / treatment targets: "Bacterial mRNA Translation by the Ribosome" (the shared ribosomal target of tetracyclines, macrolides, aminoglycosides, lincosamides, chloramphenicol, oxazolidinones) and "Suppression of Toxin and Exoprotein Synthesis" (the adjunctive anti-toxin rationale for clindamycin/linezolid in toxin-mediated disease). Nodes are druggable steps, not individual drugs.
Bacterial mRNA Translation by the Ribosome
therapeutic vulnerability
The bacterial 70S ribosome translates mRNA into protein through decoding at the 30S subunit and peptide-bond formation at the 50S peptidyl transferase centre. This essential process is the second major antibiotic target after the cell wall. Drug classes bind distinct sites: aminoglycosides and tetracyclines act on the 30S (aminoglycosides cause misreading and are bactericidal; tetracyclines block A-site tRNA and are bacteriostatic), while macrolides, lincosamides (clindamycin), chloramphenicol, and oxazolidinones (linezolid) act on the 50S. Bacterial ribosomes differ enough from the eukaryotic 80S ribosome to give these drugs selective toxicity.
Used by disorders
Leptospirosis
as Leptospiral Ribosomal Translation (Doxycycline Target)
Lyme Disease
as Borrelial Ribosomal Translation (Doxycycline Target)
Murine typhus
as Rickettsial Ribosomal Translation (Tetracycline Target)
Oroya fever
as Bartonella Ribosomal Translation (Chloramphenicol Target)
Pertussis
as Bacterial Ribosomal Translation (Macrolide Target)
Psittacosis
as Chlamydial Ribosomal Translation (Tetracycline Target)
Q Fever
as Coxiella Ribosomal Translation (Tetracycline Target)
Scarlet Fever
as Streptococcal Ribosomal Translation (Clindamycin/Macrolide Target)
Yaws
as Treponemal Ribosomal Translation (Azithromycin Target)
Downstream
-
Suppression of Toxin and Exoprotein Synthesis
Inhibiting translation also halts synthesis of secreted toxins and exoproteins, an effect exploited adjunctively in toxin-mediated disease.
-
Ribosomal Target Resistance
Bacteria protect the ribosomal target from these drugs, escaping protein-synthesis inhibition.
Suppression of Toxin and Exoprotein Synthesis
therapeutic vulnerability
Because secreted toxins and virulence exoproteins are themselves translated products, ribosome-targeting drugs shut off their production independently of bacterial killing. Clindamycin and linezolid retain this anti-toxin effect at high bacterial densities and in stationary phase, where beta-lactams lose efficacy (the inoculum/Eagle effect). This is the mechanistic basis for adding a protein-synthesis inhibitor to a beta-lactam in toxin-driven streptococcal toxic shock, necrotizing soft-tissue infection, and staphylococcal toxic shock — the bactericidal agent clears the organism while the ribosomal agent silences toxin output.
Used by disorders
Scarlet Fever
as Streptococcal Exotoxin Synthesis Suppression by Protein-Synthesis Inhibitors
Ribosomal Target Resistance
adaptive escape
Bacteria acquire resistance to ribosome-targeting drugs by modifying or protecting the target: methylation of 23S rRNA by erm methyltransferases confers macrolide-lincosamide-streptogramin B (MLSb) resistance, ribosomal protein/rRNA mutations and ribosomal protection proteins block tetracyclines, and aminoglycoside-modifying enzymes inactivate aminoglycosides. Efflux pumps remove several classes. This node explains why a ribosome-active agent can fail against a specific organism and why inducible clindamycin resistance must be excluded before relying on clindamycin's anti-toxin effect.